Opinion: Understanding and Coping With Rising Publication Costs

As article processing charges top $5,000 at some research journals, authors and institutions have means of negotiating better deals or finding less expensive options.

Written byM. Bishr Omary and Theodore S. Lawrence
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

© ISTOCK.COM/KMLMTZ66A highlight in the career of any biomedical investigator, from a trainee to an established scientist, is when a research study is ready to be submitted for publication. Increasingly, this sense of gratification may be offset by sticker shock at the article processing charges (APCs) associated with publication. In the process of conducting research, writing and submitting a paper, and addressing reviewer and editor comments, APCs are often not at the front of an investigator’s mind. However, APCs have increased significantly, and authors’ historical indifference to publication fees may be changing as a result.

There are large variations in APCs—publication costs per manuscript can range from minimal or no fees to more than $5,000. These charges are influenced by a number of factors, including the journal and/or publisher, page count of the article, and the number and type of images. Open access (OA) journals include access fees in the APC; many other publishers offer optional open access for an additional fee.

To understand some of the issues that may be driving the rise in publication fees, one needs to consider multiple and competing factors, including costs borne by publishers to bring an article (and a journal) to its final formatted state, as well as the cost recovery and potential profits generated by not only APCs but also revenue streams ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

September 2017

Healing with Hallucinogens

The therapeutic benefits of psychedelic drugs

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies